In Vitro Performance Characteristics of Valved Holding Chamber and Spacer Devices with a Fluticasone Metered-Dose Inhaler

Pharmacotherapy

Volumn 24, Issue 2 I, 2004, Pages 159-166

  Asmus, Michael J ^a   Liang, Judy ^a   Coowanitwong, Intira ^a   Hochhaus, Günther ^a  

^a UNIVERSITY OF FLORIDA HEALTH   (United States)

Author keywords

Fluticasone; In vitro study; Metered dose inhaler; Spacer device; Valved holding chamber

Indexed keywords

FLUTICASONE; FLUTICASONE PROPIONATE; METHANOL;

AEROSOL; ANALYSIS OF VARIANCE; ARTICLE; DEVICE; DRUG DELIVERY SYSTEM; DRUG DETERMINATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; METERED DOSE INHALER; OUTCOMES RESEARCH; PERFORMANCE; SPACER DEVICE; UNITED STATES; VALVED HOLDING CHAMBER DEVICE;

AEROSOLS; ANDROSTADIENES; DRUG DELIVERY SYSTEMS; EQUIPMENT DESIGN; FORECASTING; INHALATION; INHALATION SPACERS; PARTICLE SIZE; PEAK EXPIRATORY FLOW RATE;

EID: 1142274351     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.24.2.159.33147     Document Type: Article

References (35)

1. Terzano C. Pressurized metered dose inhalers and add-on devices. Pulm Pharmacol Ther 2001;14:351-66.
2. National Asthma Education and Prevention Program. Expert panel report 2: guidelines for the diagnosis and management of asthma. Publication no. 97-4051.10. Bethesda, MD: National Institutes of Health-U.S. Department of Health and Human Services, 1997.
3. Kim CS, Eldridge MA, Sackner MA. Oropharyngeal deposition and delivery aspects of metered-dose inhaler aerosols. Am Rev Respir Dis 1987;135:157-64.
4. Ahrens R, Lux C, Bahl T, Han S. Choosing the metered-dose inhaler spacer or holding chamber that matches the patient's need: evidence that specific drug being delivered is an important consideration. J Allergy Clin Immunol 1995;96:288-94.
5. Finlay WH, Zuberbuhler P, Mandl M. Particle size measurements for Space Chamber metered dose inhaler holding chamber compared with AeroChamber and metered dose inhaler alone. J Aerosol Med 1997;10:213-19.
6. Kelly HW, Ahrens RC, Holmes M, et al. Evaluation of particle size distribution of salmeterol administered via metered-dose inhaler with and without valved holding chambers. Ann Allergy Asthma Immunol 2001;87:482-7.
7. Berlinski A, Waldrep JC. Metering performance of several metered-dose inhalers with different spacers/holding chambers. J Aerosol Med 2001;14:427-32.
8. Watt PM, Clements B, Devadason SG, Chaney GM. Funhaler spacer: improving adherence without compromising delivery. Arch Dis Child 2003;88:579-81.
9. Gunawardena KA, Sohal T, Jones JI, Upchurch FC, Crompton GK. The spacehaler for delivery of salbutamol: a comparison with the standard metered-dose inhaler plus volumatic spacer device. Respir Med 1997;91:311-16.
10. Santati S, Preuthipan A. Clinical comparison of a homemade fruit juice spacer and two standard spacers in children [abstr]. Am J Resp Crit Care Med 2000;161:A343.
11. Rau JL, Zhu Y. Reservoir design and dose availability with long-term metered dose inhaler corticosteroid use. J Aerosol Med 1998;11:15-26.
12. Finlay WH, Zuberbuhler P. In vitro comparison of beclomethasone and salbutamol metered-dose inhaler aerosols inhaled during pediatric tidal breathing from four valved holding chambers. Chest 1998;114:1676-80.
13. Dalby RN, Somaraju S, Chavan VS, Jarvis D. Evaluation of aerosol drug output from the OptiChamber and AeroChamber spacers in a model system. J Asthma 1998;35:173-7.
14. Berg E, Madsen J, Bisgaard H. In vitro performance of three combinations of spacers and pressurized metered dose inhalers for treatment in children. Eur Respir J 1998;12:472-6.
15. Barry PW, O'Callaghan C. A comparative analysis of the particle size output of beclomethasone diproprionate, salmeterol xinafoate and fluticasone propionate metered dose inhalers used with the Babyhaler, Volumatic and AeroChamber spacer devices. BrJ Clin Pharmacol 1999;47:357-60.
16. Barry PW, O'Callaghan C. The output of budesonide from spacer devices assessed under simulated breathing conditions. J Allergy Clin Immunol 1999;104:1205-10.
17. Vaczek D. Top 200 drugs of 2002. Pharm Times 2003;69:20-6.
18. Olson B. Can in vitro measurements predict the lung deposition of dry-powder inhalers? J Aerosol Med 1997;10:S13-16.
19. The United States Pharmacopeial Convention. Physical tests and determinations: aerosols, metered-dose inhalers and dry-powder inhalers. In: The United States Pharmacopeia, 25th ed. Rockville, MD: USP Convention, 2001:1964-80.
20. Phelan RF, Cuddihy RG, Fisher GL, et al. Main features of the proposed NCRP respiratory tract model. Radiat Prot Dosimetry 1991;38:179-84.
21. Task Group on Lung Dynamics. Deposition and retention models for internal dosimetry of the human respiratory tract. Health Phys 1966;12:173-208.
22. 2-agonist and anticholinergic aerosols in patients with severe airflow obstruction. Thorax 1996;51:977-80.
23. Bisgaard H. What dose fraction represents the respirable dose? Respir Med 1997;91(suppl A):20-1.
24. GlaxoSmithKline Inc. Flovent (fluticasone propionate 220-μg inhalation aerosol) package insert. Research Triangle Park, NC; 2001.
25. Iula AK, Flynn CL, Deluccia F. Comparative study of the in vitro dose delivery and particle size distribution characteristics of an azmacort metered-dose inhaler in combination with four different spacer devices. Curr Ther Res 1997;58:544-54.
26. Chew NY, Chan HK. The effect of spacers on the delivery of metered dose aerosols of nedocromil sodium and disodium cromoglycate. Int J Pharm 2000;200:87-92.
27. Wilkes W, Fink J, Dhand R. Selecting an accessory device with a metered-dose inhaler: variable influence of accessory devices on fine particle dose, throat deposition, and drug delivery with asynchronous actuation from a metered-dose inhaler. J Aerosol Med 2001;14:351-60.
28. Feddah MR, Davies NM, Gipps EM, Brown KF. Influence of respiratory spacer devices on aerodynamic particle size distribution and fine particle mass of beclomethasone from metered-dose inhalers. J Aerosol Med 2001;14:477-85.
29. Nagel MW, Wiersema KJ, Bates SL, Mitchell JP. Performance of large- and small-volume valved holding chambers with a new combination long-term bronchodilator/anti-inflammatory formulation delivered by pressurized metered dose inhaler. J Aerosol Med 2002;15:427-33.
30. Newman SP. How well do in vitro particle size measurements predict drug delivery in vivo? J Aerosol Med 1998;11(suppl 1):S97-104.
31. Newman SP, Wilding IR, Hirst PH. Human lung deposition data: the bridge between in vitro and clinical evaluations for inhaled drug products? Int J Pharm 2000;208:49-60.
32. Smith KJ, Chan HK, Brown KF. Influence of flow rate on aerosol particle size distributions from pressurized and breath-actuated inhalers. J Aerosol Med 1998;11:231-45.
33. Feddah MR, Brown KF, Gipps EM, Davies NM. In-vitro characterization of metered dose inhaler versus dry powder inhaler glucocorticoid products: influence of inspiratory flow rates. J Pharm Sci 2000;3:318-24.
34. Bousquet J, Ben-Joseph R, Messonnier M, et al. A meta-analysis of the dose-response relationship of inhaled corticosteroids in adolescents and adults with mild to moderate persistent asthma. Clin Ther 2002;24:1-20.
35. Martin RJ, Szefler SJ, Chinchilli VM, et al. Systemic effect comparisons of six inhaled corticosteroid preparations. Am J Respir Crit Care Med 2002;165:1377-83.